Find recruiting clinical trials for coronary artery disease (CAD) in the UK — including novel lipid-lowering agents, anti-inflammatory strategies, next-generation antiplatelet therapies, and precision medicine approaches. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
No established CAD but high risk — managing risk factors
Standard: Statins (atorvastatin, rosuvastatin), lifestyle modification, blood pressure control, diabetes management
Established coronary disease with stable symptoms
Standard: Aspirin, statins, beta-blockers, calcium channel blockers, nitrates, GTN spray as required
Heart attack or unstable angina requiring hospital admission
Standard: Dual antiplatelet therapy (ticagrelor + aspirin), primary PCI, statin loading, anticoagulation
Following stent or bypass surgery — preventing recurrence
Standard: Lifelong aspirin, P2Y12 inhibitors (clopidogrel, ticagrelor), high-intensity statin, ezetimibe if needed
Next-generation PCSK9 inhibitors, oral small-molecule PCSK9 blockers, APOC3 and Lp(a) antisense therapy, bempedoic acid combinations, and ANGPTL3 inhibitors for refractory hyperlipidaemia.
Low-dose colchicine for secondary prevention, canakinumab and other IL-1β targeted therapies, methotrexate in CAD — building on the landmark CANTOS trial to reduce residual inflammatory risk.
Factor XI inhibitors that promise effective thromboprophylaxis with lower bleeding risk, new P2Y12 agents, and tailored dual-pathway inhibition strategies for patients with both CAD and atrial fibrillation.
Genetics-guided antiplatelet selection (CYP2C19 testing), CT coronary angiography follow-up protocols, and novel PET/CT tracers to identify high-risk vulnerable plaques before they rupture.
Loading trials from ClinicalTrials.gov...
Yes. Many CAD trials enrol patients with prior revascularisation, particularly studies testing secondary prevention agents or treatments to prevent in-stent restenosis.
Novel PCSK9 inhibitors beyond inclisiran, anti-inflammatory agents targeting interleukin-1β (CANTOS pathway), low-dose colchicine for secondary prevention, and new oral anticoagulant strategies for patients with concomitant atrial fibrillation.
Yes. NHS cardiology departments across the UK — including BHF Centres of Excellence in London, Cambridge, Oxford, Glasgow, and Leicester — are actively recruiting for CAD trials covering everything from primary prevention to advanced coronary disease.
Yes. Several trials are testing optimal medical therapy alone versus revascularisation in stable CAD. These studies compare modern drug regimens — including intensified statins, ezetimibe, and novel anti-inflammatory agents — directly with interventional approaches.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or cardiologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.